Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PTCT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPTC Therapeutics reports Q2 revenue of $361M, raises 2026 guidance on Sephience momentum
Filed July 30, 2026 · Period ending July 28, 2026 · ~2 min read
Key Changes
-
high
Q2 2026 total revenue reached $361M with product revenue of $239M, more than doubling year-over-year; company swung to net income of $83.5M from a $64.8M loss in Q2 2025, driven by commercial portfolio strength.
Exhibit 99.1 view on EDGAR → -
high
Sephience generated $151M in Q2 revenue, up 21% sequentially from Q1, with 1,647 patients on commercial therapy globally as of June 30; full-year product revenue guidance raised to $850-950M from prior $750-850M range.
Exhibit 99.1 view on EDGAR → -
medium
PTC received a $50M milestone payment from Novartis upon dosing the first patient in the INVEST-HD Phase 3 study of votoplam for Huntington's disease; Novartis is conducting and funding the trial targeting ~770 participants.
Exhibit 99.1 view on EDGAR → -
medium
Company issued $550M of 0% coupon senior convertible notes due 2031 with conversion price at 40% premium, concurrently repurchasing majority of 1.5% notes due September 2026; cash and marketable securities rose to $2.2B from $1.9B at year-end 2025.
Exhibit 99.1 view on EDGAR → -
low
Former CHRO Hege Sollie-Zetlmayer appointed to Board as Class III director effective July 28, 2026, filling a vacancy with term expiring at 2028 annual meeting; receives standard non-employee director compensation and equity grants.
Item 5.02 verify on EDGAR →
Summary
PTC Therapeutics delivered strong second-quarter results with total revenue of $361 million and a swing to profitability, reporting net income of $83.5 million versus a $64.8 million loss in the prior-year period. The commercial portfolio more than doubled product revenue year-over-year to $239 million, led by Sephience's $151 million in sales and 21% sequential growth.
Management raised full-year product revenue guidance by $100 million at the midpoint to reflect the momentum, now expecting $850-950 million for 2026. The quarter also brought a $50 million milestone payment from Novartis tied to the start of the INVEST-HD Phase 3 trial for votoplam in Huntington's disease, a Novartis-funded study targeting approximately 770 participants.
PTC refinanced its near-term debt by issuing $550 million in zero-coupon convertible notes due 2031 at a 40% conversion premium and retiring most of its September 2026 notes, ending the quarter with $2.2 billion in cash and marketable securities. The company also appointed former CHRO Hege Sollie-Zetlmayer to the Board, filling a vacancy with a director familiar with the organization. For holders, the key takeaway is accelerating commercial execution translating to profitability and an improved balance sheet, with the raised guidance signaling confidence in sustained growth.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
PTC Therapeutics announced Q2 2026 financial results via press release.
Added in current filing · verify on EDGAR →
On July 30, 2026, PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026.
The company disclosed its second quarter 2026 financial results. The 8-K itself provides no quantitative details; all financial metrics are contained in the press release furnished as Exhibit 99.1, which is not included in this filing body.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On July 28, 2026, the Company appointed Hege Sollie-Zetlmayer to its board of directors (the “Board”), effective immediately, filling a vacancy on the Board. Ms. Sollie-Zetlmayer will serve as a Class III director with a term expiring at the annual meeting of stockholders to be held in 2028.
PTC appointed Hege Sollie-Zetlmayer to the Board as a Class III director, filling a vacancy. Her term expires at the 2028 annual meeting. Ms. Sollie-Zetlmayer retired as Chief Human Resources Officer in June 2026 after eight years with the company.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
In connection with Ms. Sollie-Zetlmayer’s appointment to the Board, she will be entitled to compensation in accordance with the Company’s outside director compensation policy, under which each non-employee director receives a base annual retainer of $50,000 per year for service as a Board member.
Ms. Sollie-Zetlmayer will receive the standard non-employee director compensation: a $50,000 annual retainer plus reimbursement for reasonable meeting-related expenses. This is consistent with the company's existing outside director compensation policy.
Added in current filing · verify on EDGAR →
the Company granted Ms. Sollie-Zetlmayer, pursuant to the Company’s Amended and Restated 2013 Long-Term Incentive Plan, (i) an “initial director equity grant” consisting of 3,475 stock options to purchase shares of the Company’s common stock, which vest equally on a monthly basis over 36 months beginning on the one month anniversary of the grant date and 4,000 restricted stock units, which shares underlying such restricted stock units vest in three equal annual installments commencing on July 28, 2027, and (ii) an “annual director equity grant”, pro-rated for the remainder of 2026, consisting of 1,738 stock options to purchase shares of the Company’s common stock, which vest in six equal monthly installments commencing on August 2, 2026, and 2,000 restricted stock units, with the shares underlying such restricted stock units vesting on January 2, 2027.
Ms. Sollie-Zetlmayer received two equity grants under the company's standard director equity policy: an initial grant (3,475 options vesting monthly over 36 months, 4,000 RSUs vesting annually over 3 years) and a pro-rated 2026 annual grant (1,738 options vesting monthly over 6 months, 2,000 RSUs vesting January 2027). Beginning in 2027, she will receive equity grants on the same terms as other continuing directors.
Event · Item 7.01 — Regulation FD Disclosure
PTC Therapeutics announces Q2 2026 earnings conference call scheduled for July 30, 2026 at 4:30 p.m. ET.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company will host a conference call on July 30, 2026 at 4:30 p.m. eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended June 30, 2026, as well as other corporate highlights and updates.
PTC Therapeutics will hold a conference call on July 30, 2026 at 4:30 p.m. ET to discuss Q2 2026 financial results and provide corporate updates. This is a routine quarterly earnings disclosure event.
Event · Exhibit 99.1
PTC reports Q2 2026 revenue of $361M, raises full-year guidance, and advances pipeline including new Huntington's disease candidate PTC303.
Added in current filing · view on EDGAR →
Expected total revenue increased to $1.18 to $1.28 billion, with total product revenue guidance raised to $850 to $950 million from $750 to $850 million
PTC raised its full-year 2026 total revenue guidance to $1.18 to $1.28 billion and increased product revenue guidance to $850 to $950 million from a prior range of $750 to $850 million, reflecting strong commercial momentum.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 31, 2026 · How we verify